Abstract
Bipolar disorder is an often-severe mental health disorder characterized by alternation between extreme mood states of mania and depression. Despite strong heritability and the recent identification of 64 loci of small effect, pathophysiological mechanisms and much of the genetic risk remain unknown. Here, through genome sequencing and linkage and association analyses, we found that rare variants co-segregating with bipolar disorder in large multiply affected families cluster within gene networks enriched for synaptic and nuclear functions. The top variant in this analysis prioritized by statistical association, predicted deleteriousness, and network centrality was a missense variant in the gene encoding D-amino acid oxidase (DAOG131V). Heterologous expression of DAOG131V in human cells resulted in decreased DAO protein abundance and enzymatic activity. In a knock-in mouse harboring this human DAOG131V variant, DaoG130V/+, we similarly found decreased DAO protein abundance, as well as enhanced stress susceptibility and blunted behavioral responses to pharmacological inhibition of N-methyl-D-aspartate receptors (NMDARs). RNA sequencing of cerebellar tissue revealed that DaoG130V resulted in decreased expression of two gene networks that are enriched for synaptic functions and for genes expressed specifically in Purkinje cells and granule neurons. Similar expression changes in both of these gene networks were also identified in the cerebellum of bipolar disorder cases vs. controls. These findings implicate dysregulation of NMDAR signaling and of gene expression in cerebellar neurons in bipolar disorder pathophysiology and provide insight into its genetic architecture.
One Sentence Summary Functional studies of a rare hypofunctional variant in the D-amino acid oxidase gene implicate stress susceptibility, NMDA receptor signaling, and cerebellar circuits in risk for bipolar disorder.
Competing Interest Statement
Dr. Nurnberger is an investigator for Janssen. All other authors declare that they have no competing interests. The contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.
Funding Statement
Funding was provided by the National Institute of Mental Health (R01 MH094483, JRK; R01 MH110437, PPZ), the National Institute of General Medical Sciences (P50 GM076547, Leroy Hood), the Intramural Research Program of the National Institute of Mental Health (FJM), the U.S. Department of Veterans Affairs Merit Awards I01BX004062 and 101BX003631 (TDG), the University of Luxembourg and Institute for Systems Biology Strategic Partnership (Leroy Hood, principal investigator), a NARSAD Young Investigator Award from the Brain and Behavior Research Foundation (SAA), and seed funding from the University of Maryland School of Medicine (SAA). Data and biomaterials were collected as part of 11 projects (Study 40) that participated in the NIMH Bipolar Disorder Genetics Initiative (MH59545, MH059534, MH59533, MH59553, MH60068, MH059548, MH59535, MH59567, MH059556, and 1Z01MH002810-01), which was also supported by NIH Grants P50CA89392, from the National Cancer Institute, and 5K02DA021237, from the National Institute of Drug Abuse.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used fully de-identified data from human cohorts. The use of these data was approved as exempt by the University of Maryland Baltimore IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Genome sequences have been deposited in the BIGPOWER database and are available upon request to Dr. Jared Roach (jedroach{at}uw.edu). RNA-seq data have been deposited in the Gene Expression Omnibus (GSE# in progress). The DaoG130V/+ mouse line has been made available through the Mutant Mouse Resource and Research Centers (RRID:MMRRC_067164-UCD). All other data are available in the main text or the supplementary materials.